Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

9

Revenue 2017

Lantus

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Lantus was produced by Sanofi.

Sanofi sells European generics to Advent for $2.4bn

Sanofi sells European generics to Advent for $2.4bn

Sanofi is in the midst of a shakedown of its business prompted by a decline in sales of its diabetes blockbuster Lantus (insulin glargine) and the failure of some other products

The good, the bad and the ugly

The good, the bad and the ugly Sanofi’s Lantus (-18.8%), Amgen’s Enbrel (-10.8%) and Gilead’s Harvoni (-48.5%) are among those whose revenues have fallen sharply.

Third time lucky? Sanofi cuts an $11.6bn deal to buy Bioverativ

Third time lucky? Sanofi cuts an $11.6bn deal to buy Bioverativ Sanofi needs to deliver some big new products as it faces a slowdown in diabetes sales following the loss of patent protection for blockbuster Lantus (insulin glargine) and increased competition driving

Novartis doubles down on biosimilars with Biocon alliance

Novartis doubles down on biosimilars with Biocon alliance Biocon meanwhile has launched an insulin glargine biosimilar in Japan to rival Sanofi’s Lantus brand, trastuzumab and Roche’s Avastin (bevacizumab) biosimilars in India and recombinant human insulin, insulin glargine

Result pages: 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 ()

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
WCG

WCG is an independent, global agency specialising in healthcare communications. Our value as a company is about being the positive...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics